WO2020106461A3 - Anti-mertk antibodies and methods of use thereof - Google Patents

Anti-mertk antibodies and methods of use thereof Download PDF

Info

Publication number
WO2020106461A3
WO2020106461A3 PCT/US2019/060223 US2019060223W WO2020106461A3 WO 2020106461 A3 WO2020106461 A3 WO 2020106461A3 US 2019060223 W US2019060223 W US 2019060223W WO 2020106461 A3 WO2020106461 A3 WO 2020106461A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mertk
mertk antibodies
antibodies
modulate
Prior art date
Application number
PCT/US2019/060223
Other languages
French (fr)
Other versions
WO2020106461A2 (en
Inventor
Tibor Keler
Joel Goldstein
Diego ALVARADO
Richard W. GEDRICH
Laura Vitale
Tom O'NEILL
Andrea CROCKER
Michael B. Murphy
Original Assignee
Celldex Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics, Inc. filed Critical Celldex Therapeutics, Inc.
Publication of WO2020106461A2 publication Critical patent/WO2020106461A2/en
Publication of WO2020106461A3 publication Critical patent/WO2020106461A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Provided herein are compositions, methods and uses involving antibodies that specifically bind to MerTK, a receptor tyrosine kinase, and modulate the expression and/or activity of MerTK. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer.
PCT/US2019/060223 2018-11-08 2019-11-07 Anti-mertk antibodies and methods of use thereof WO2020106461A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862757651P 2018-11-08 2018-11-08
US62/757,651 2018-11-08
US201962826301P 2019-03-29 2019-03-29
US62/826,301 2019-03-29

Publications (2)

Publication Number Publication Date
WO2020106461A2 WO2020106461A2 (en) 2020-05-28
WO2020106461A3 true WO2020106461A3 (en) 2020-09-03

Family

ID=70774147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/060223 WO2020106461A2 (en) 2018-11-08 2019-11-07 Anti-mertk antibodies and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2020106461A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114364703A (en) * 2019-04-19 2022-04-15 豪夫迈·罗氏有限公司 Anti-merk antibodies and methods of use thereof
BR112022011570A2 (en) 2019-12-13 2022-12-13 Alector Llc ANTI-MERTK ANTIBODIES AND METHODS OF THEIR USE
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040123343A1 (en) * 2000-04-19 2004-06-24 La Rosa Thomas J. Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20060093599A1 (en) * 2004-11-03 2006-05-04 Gadi Gazit-Bornstein Anti-properdin antibodies, and methods for making and using same
WO2010032059A2 (en) * 2008-09-19 2010-03-25 Medimmune Llc Targeted binding agents directed to cd105 and uses thereof
WO2014159010A1 (en) * 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1
US20140314784A1 (en) * 2011-07-20 2014-10-23 Medlmmune Limited Anti-cxcr4 antibodies and methods of use
WO2016127179A2 (en) * 2015-02-06 2016-08-11 Kadmon Corporation, Llc Immunomodulatory agents
US20180002444A1 (en) * 2014-12-22 2018-01-04 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2018128973A1 (en) * 2017-01-03 2018-07-12 Regeneron Pharmaceuticals, Inc. Human antibodies to s. aureus hemolysin a toxin

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040123343A1 (en) * 2000-04-19 2004-06-24 La Rosa Thomas J. Rice nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20060093599A1 (en) * 2004-11-03 2006-05-04 Gadi Gazit-Bornstein Anti-properdin antibodies, and methods for making and using same
WO2010032059A2 (en) * 2008-09-19 2010-03-25 Medimmune Llc Targeted binding agents directed to cd105 and uses thereof
US20140314784A1 (en) * 2011-07-20 2014-10-23 Medlmmune Limited Anti-cxcr4 antibodies and methods of use
WO2014159010A1 (en) * 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to grem 1
US20180002444A1 (en) * 2014-12-22 2018-01-04 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
WO2016127179A2 (en) * 2015-02-06 2016-08-11 Kadmon Corporation, Llc Immunomodulatory agents
WO2018128973A1 (en) * 2017-01-03 2018-07-12 Regeneron Pharmaceuticals, Inc. Human antibodies to s. aureus hemolysin a toxin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KASIKARA ET AL.: "Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression", MOL CANCER RES., vol. 15, no. 6, 2017, pages 753 - 764, XP055460517, DOI: 10.1158/1541-7786.MCR-16-0350 *

Also Published As

Publication number Publication date
WO2020106461A2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
WO2020106461A3 (en) Anti-mertk antibodies and methods of use thereof
WO2017035430A3 (en) Anti-alk antibodies and methods for use thereof
JOP20210330A1 (en) Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
EA202190377A9 (en) CXCR4 INHIBITOR COMPOSITIONS AND METHODS FOR PREPARATION AND APPLICATION
CL2019002270A1 (en) Antibody and anti-egfr drug conjugates. (divisional request 201803527)
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
MX2018009752A (en) Substituted 1,2,3-triazoles as nr2b-selective nmda modulators.
MX2021015500A (en) Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators.
WO2017156495A8 (en) Compounds and methods for modulating bruton's tyrosine kinase
AU2016219704A1 (en) Anti-Notch1 antibodies
MX2022004937A (en) Inhibitors of raf kinases.
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2019236775A8 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CR20210580A (en) Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
MY194603A (en) Anti-Complement Factor Bb Antibodies And Uses Thereof
WO2019051327A3 (en) Agents modulating beta-catenin functions and methods thereof
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
WO2018067520A3 (en) Therapeutic agents and methods:
WO2015179737A3 (en) Treatment of eosinophil or mast cell related disorders
JOP20220107A1 (en) Allosteric egfr inhibitors and methods of use thereof
WO2021048564A3 (en) Antigen-binding domain
MX2020003126A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19887896

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19887896

Country of ref document: EP

Kind code of ref document: A2